Misplaced Pages

Ateganosine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Ateganosine
Clinical data
Other names2'-Deoxythioguanosine
Identifiers
IUPAC name
  • 2-amino-9--3H-purine-6-thione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13N5O3S
Molar mass283.31 g·mol
3D model (JSmol)
SMILES
  • C1((O1N2C=NC3=C2NC(=NC3=S)N)CO)O
InChI
  • InChI=InChI=1S/C10H13N5O3S/c11-10-13-8-7(9(19)14-10)12-3-15(8)6-1-4(17)5(2-16)18-6/h3-6,16-17H,1-2H2,(H3,11,13,14,19)/t4-,5+,6+/m0/s1
  • Key:SCVJRXQHFJXZFZ-KVQBGUIXSA-N

Ateganosine is a telomerase inhibitor and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).

References

  1. Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1): 672. Bibcode:2024NatCo..15..672E. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.
  2. "Ateganosine". PatSnap.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: